Why Naltrexone Is the Missing Link in Opioid Overdose Prevention

I recently read: Methadone Industrial Complex and the Lost Cure for Opioid Addiction - Randy Bock MD PC

Medication-Assisted Treatment (MAT), now more commonly referred to as Medications for Opioid Use Disorder (MOUD), is a broad term describing medications used in the treatment of opioid addiction. There are three primary medications in this category: methadone, buprenorphine, and naltrexone.

In practice, MOUD most often refers to methadone and buprenorphine. Both are opioids themselves and are used as substitution therapies in treating opioid addiction. Because of their opioid nature, these medications are subject to strict regulations due to the risks of diversion, misuse, and overdose. A more precise term for this approach is Opioid Substitution Treatment (OST).

However, OST tends to be less effective in environments where the supply of illicit opioids remains uncontrolled. This is a topic I have explored in previous posts. Given these limitations, it is not surprising that the United States has experienced over one million opioid-related overdose deaths since 1995.

The third medication, naltrexone, differs significantly. It is not an opioid, yet it is included in the MOUD category. Despite its unique properties, it remains significantly underutilized—an issue that deserves greater attention. Historically, substantial funding has been directed toward promoting methadone and buprenorphine. For example, during the Nixon administration’s efforts to combat the heroin epidemic of the 1960s and 1970s, tens of millions of dollars were invested in establishing methadone programs. Rarely in U.S. history has such a concentrated effort been made to expand access to a single treatment approach. For those interested in this history, I recommend Addiction, Inc. by Emily Dufton.

Federal agencies have long been aware of the limitations associated with opioid-based treatments like methadone and buprenorphine. Naltrexone was developed as a non-opioid alternative, designed to help prevent relapse in individuals who have discontinued opioid use, including those transitioning off methadone or buprenorphine. However, the level of funding and education needed to support widespread adoption of naltrexone has not been comparable.

Naltrexone may be better understood not simply as a treatment, but as a preventive tool. In that sense, it aligns more closely with what could be described as Medication-Assisted Prevention (MAP). If reducing opioid overdose deaths is a priority, the unique pharmacological benefits of naltrexone should not be overlooked. While naloxone (Narcan) has been widely deployed as a life-saving intervention to reverse overdoses, naltrexone represents a logical next step in preventing them altogether.

If you would like to connect with Percy Menzies, M. Pharm., regarding this article, you can reach him through his LinkedIn profile.”